Entrada Therapeutics, Inc.
General ticker "TRDA" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $394.7M (TTM average)
Entrada Therapeutics, Inc. does not follow the US Stock Market performance with the rate: -24.0%.
Estimated limits based on current volatility of 7.2%: low 4.36$, high 5.03$
Factors to consider:
- Total employees count: 152 (-16.9%) as of 2025
- Top business risk factors: Operational and conduct risks, Limited operating history, Therapeutic candidate dependency, Early stage company, Market competition
- Current price 38.8% below estimated low
- Earnings for 6 months up through Q2 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [7.14$, 15.14$]
- 2026-12-31 to 2027-12-31 estimated range: [6.44$, 13.89$]
Financial Metrics affecting the TRDA estimates:
- Negative: with PPE of -3.0 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: negative Operating cash flow
- Negative: negative Industry operating cash flow (median)
- Negative: Inventory ratio change, % of 4.76 > 4.02
- Negative: negative Net income
- Positive: 69.38 < Shareholder equity ratio, % of 81.12 <= 81.92
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term TRDA quotes
Long-term TRDA plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $129.01MM | $210.78MM | $25.42MM |
| Operating Expenses | $132.18MM | $163.77MM | $181.42MM |
| Operating Income | $-3.16MM | $47.01MM | $-156.00MM |
| Non-Operating Income | $15.22MM | $19.47MM | $13.17MM |
| R&D Expense | $99.88MM | $125.31MM | $142.27MM |
| Income(Loss) | $12.06MM | $66.48MM | $-142.83MM |
| Taxes | $18.74MM | $0.86MM | $0.92MM |
| Net Income(Loss)* | $-6.68MM | $65.63MM | $-143.75MM |
| Stockholders Equity | $242.36MM | $428.68MM | $306.13MM |
| Assets | $469.19MM | $526.32MM | $377.38MM |
| Operating Cash Flow | $139.80MM | $-41.56MM | $-128.51MM |
| Capital expenditure | $5.61MM | $3.16MM | $1.04MM |
| Investing Cash Flow | $-138.40MM | $-27.80MM | $116.81MM |
| Financing Cash Flow | $21.04MM | $102.96MM | $0.89MM |
| Earnings Per Share** | $-0.20 | $1.76 | $-3.47 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.